Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.

Song IH, Maksymowych WP.

Rheum Dis Clin North Am. 2012 Aug;38(3):613-33. doi: 10.1016/j.rdc.2012.08.004. Epub 2012 Sep 15. Review.

PMID:
23083759
2.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.

Ann Rheum Dis. 2008 Sep;67(9):1276-81. Epub 2007 Nov 15.

PMID:
18006539
3.

An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D.

Ann Rheum Dis. 2006 Dec;65(12):1620-5. Epub 2006 Feb 7.

4.

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J.

Rheumatology (Oxford). 2005 Dec;44(12):1525-30. Epub 2005 Aug 9.

PMID:
16091396
5.

New therapeutic approaches for spondyloarthritis.

Manadan AM, James N, Block JA.

Curr Opin Rheumatol. 2007 May;19(3):259-64. Review.

PMID:
17414952
6.

Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.

Henderson C, Davis JC.

Nat Clin Pract Rheumatol. 2006 Apr;2(4):211-8. Review.

PMID:
16932687
7.

Effects of low-dose infliximab on spinal inflammation on magnetic resonance imaging in ankylosing spondylitis.

Rudwaleit M.

J Rheumatol. 2010 Aug 1;37(8):1553-5. doi: 10.3899/jrheum.100422. No abstract available.

PMID:
20675850
8.

BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.

Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P; BSR Standards, Guidelines and Audit Working group.

Rheumatology (Oxford). 2005 Jul;44(7):939-47. Epub 2005 May 18. No abstract available.

PMID:
15901904
9.

Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy.

Baraliakos X, Listing J, Haibel H, Sieper J, Braun J.

J Rheumatol. 2013 Nov;40(11):1891-6. doi: 10.3899/jrheum.120533. Epub 2013 Aug 1.

PMID:
23908444
10.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
11.

Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Haibel H, Sieper J.

Curr Opin Rheumatol. 2010 Jul;22(4):388-92. doi: 10.1097/BOR.0b013e32833aaf93. Review.

PMID:
20473176
12.
13.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.

Ann Rheum Dis. 2004 Jun;63(6):665-70. Epub 2004 Mar 22.

14.

Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?

Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.

Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537. No abstract available.

PMID:
18697784
15.

MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.

Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D.

Ann Rheum Dis. 2012 Dec;71(12):2002-5. doi: 10.1136/annrheumdis-2012-201999. Epub 2012 Aug 21.

PMID:
22915615
16.

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.

Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J.

Arthritis Rheum. 2006 Feb;54(2):678-81. No abstract available.

17.

Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.

Baraliakos X, Braun J.

Ann Rheum Dis. 2013 Dec;72(12):e32-3. doi: 10.1136/annrheumdis-2013-204493. Epub 2013 Sep 20. No abstract available.

PMID:
24058016
18.

Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.

Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG; CANDLE Study Group.

J Rheumatol. 2010 Aug 1;37(8):1728-34. doi: 10.3899/jrheum.091043. Epub 2010 May 1.

PMID:
20436073
19.

The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.

Borman P, Ayhan F, Ceceli E.

Rheumatol Int. 2010 Nov;30(12):1689-90. doi: 10.1007/s00296-009-1283-y. Epub 2009 Dec 15. No abstract available.

PMID:
20012962
20.

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.

Ann Rheum Dis. 2008 Mar;67(3):340-5. Epub 2007 Oct 29.

Supplemental Content

Support Center